
Viscum, all-heal, birdlime
Helixor®, Iscador®, Iscador Qu®, Lektinol™, Eurixor®, Abnoba-viscum Quercus
Derived from the aerial parts, except berries, of the plant, mistletoe preparations are used by patients for a variety of conditions including cancer, HIV, hepatitis, and degenerative joint disease. Polypeptides, including lectins and viscotoxins, are thought responsible for in vitro immune stimulant and tumor inhibition activities (1). Although orally administered products are available, all research reported in the literature has evaluated parenteral formulations of mistletoe, which are not approved for use in the United States by the Food and Drug Administration.
Mistletoe extracts have anticancer effects in vitro (21). But well-designed randomized trials are lacking. A meta-analysis analyzed 11 of these clinical trials conducted before 1994 and showed no benefit from mistletoe (1), but recent systematic reviews point to the accumulating evidence in support of mistletoe while emphasizing the need for well-designed clinical trials (17) (18). Epidemiologic data also suggest survival advantage following treatment with mistletoe (2) (3). When used in conjuction with chemotherapy, a mistletoe extract improved quality of life in a study of breast cancer patients (22). However, mistletoe was not active in metastatic colorectal cancer resistant to 5-fluorouracil and leucovorin (20).
An injectable form of mistletoe lectins was found to reduce the frequency and intensity of clinical signs and symptoms in patients with hepatitis C (4). Confirmed efficacy for other proposed claims is lacking (5) (6).
Possible adverse effects from treatment include injection site reactions (7), chills, fever, headache, leukocytosis, chest pain, orthostatic hypotension, bradycardia, diarrhea, and vomiting (8) (9). In addition, long-term use of mistletoe extracts may reduce T cell function in cancer patients (10). Toxic doses of mistletoe can produce coma, seizures, and death (11). Possible drug interactions include additive hypotensive effect from antihypertensives and antagonism of cardiac glycosides or antiarrhythmics.
Immunologic action of mistletoe is attributed to lectins. Lectins induce macrophage cytotoxicity, stimulate phagocytosis of immune cells, increase cytokine secretion (TNF-alpha, IL-1, IL-2, and IL-6), and enhance cytotoxicity effects on various cell lines in vitro (9) (12). In addition, mistletoe extracts stimulate dendritic cell maturation and activation (13) and induce apoptosis of lymphoblastic leukemia cells (14). However, analysis of mistletoe lectins and alkaloids has produced conflicting data about in vitro and animal model inhibition of cancer cell growth with mouse and human cell lines.
A recent study indicates that solubilized triterpene acid- or lectin-containing mistletoe extracts induce dose-dependent apoptosis in acute lymphoblastic leukemia cell line NALM-6 through caspase-8 and -9 dependent pathways (23).
The hypotensive effect is thought to be mediated by acetylcholine, histamine, GABA, tyramine, and flavones, although the exact mechanism of action is unknown. Controlled clinical trials in humans also yield mixed results on mistletoe's effects (4) (5) (6) (15).
Mistletoe berries and leaves are highly poisonous - more than 2 berries or 3 leaves can produce toxic effects.
(9)
Pregnant women should not consume mistletoe due to uterine stimulant activity of tyramine and unidentified constituents.
Bottom Line: Mistletoe has not been shown to treat or prevent cancer.
Extensive laboratory research has been performed with mistletoe, its extracts, and the product Iscador®. These experiments show that mistletoe extracts are able to stimulate the activity of several cells and factors of the immune system. In addition, mistletoe extracts show anti-tumor activity in mice implanted with cancers of the lung, colon, and breast. Researchers think this may be due to mistletoe's ability to prevent healthy cells from turning into cancer cells (differentiation). Mistletoe has been observed to lower blood pressure, but researchers are unsure exactly how this effect takes place.
Although orally administered mistletoe products are available, all clinical trials have evaluated only the injected forms of mistletoe, which are not approved for use in the United States by the Food and Drug Administration.